Mustang Bio Inc (MBIO)

Aug 5, 2026, 7:00 AM EDT - 16 days ago

Mustang Bio Quarterly report: Q2 2026

Jun 9, 2026, 7:00 AM EDT - 2 months ago

MindBio Completes Manufacture and Delivery of First Prototype Edge AI Intoxication and Fatigue Detection Kiosks

May 14, 2026, 8:30 AM EDT - 3 months ago

MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) Harnesses Key AI, Voice Analysis to Offer Impairment Solution

May 12, 2026, 8:44 AM EDT - 3 months ago

IBN Announces Latest Episode of The TechMediaWire Podcast featuring Justin Hanka, CEO of MindBio Therapeutics Corp.

May 12, 2026, 8:30 AM EDT - 3 months ago

MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) Leveraging AI, Voice Analysis to Develop Intoxication Detection

May 5, 2026, 7:00 AM EDT - 3 months ago

Mustang Bio Quarterly report: Q1 2026

Mar 19, 2026, 7:00 AM EDT - 5 months ago

Mustang Bio Annual report: Q4 2025

Dec 3, 2025, 7:00 AM EST - 9 months ago

Mustang Bio Proxy statement: Proxy Filing

Nov 7, 2025, 7:00 AM EST - 10 months ago

Mustang Bio Quarterly report: Q3 2025

Aug 8, 2025, 4:00 PM EDT - 1 year ago

Mustang Bio Quarterly report: Q2 2025

2025-07-07T12:35:38.000Z - 1 year ago

Mustang Bio granted orphan drug designation by FDA for MB-101

Jul 7, 2025, 8:30 AM EDT - 1 year ago

Mustang Bio Granted Orphan Drug Designation by U.S. FDA for MB-101 (IL13Ra2-targeted CAR T-cells) to Treat Astrocytomas and Glioblastoma

2025-07-01T16:25:18.000Z - 1 year ago

Mustang Bio treatment of malignant glioma granted orphan designation

May 13, 2025, 6:00 PM EDT - 1 year ago

Mustang Bio Quarterly report: Q1 2025

2025-03-05T21:40:52.000Z - 1 year ago

Mustang Bio regains compliance with Nasdaq requirement

Mar 5, 2025, 4:15 PM EST - 1 year ago

Mustang Bio Regains Compliance with Nasdaq Capital Market Requirement

FBIO

2025-02-27T22:45:21.000Z - 1 year ago

Mustang Bio exits lease for Massachusetts facility, divests equipment

ABBV

Feb 27, 2025, 4:05 PM EST - 1 year ago

Mustang Bio Announces Sale of Fixed Assets and Exit of Facility

2025-02-11T21:40:16.000Z - 1 year ago

Mustang Bio regains compliance with Nasdaq

Feb 11, 2025, 4:10 PM EST - 1 year ago

Mustang Bio Regains Compliance with Nasdaq Minimum Bid Price Requirement

Feb 10, 2025, 8:00 AM EST - 1 year ago

Mustang Bio Announces Closing of $8 Million Public Offering

2025-02-06T12:27:09.000Z - 1 year ago

Mustang Bio prices 2.66M shares at $3.01 in public offering

Feb 6, 2025, 7:00 AM EST - 1 year ago

Mustang Bio Announces Pricing of $8 Million Public Offering

Feb 5, 2025, 7:00 AM EST - 1 year ago

Mustang Bio Registration statement: Registration Filing

2025-01-16T00:51:00.000Z - 1 year ago

Mustang Bio trading halted, news pending

2025-01-15T21:20:13.000Z - 1 year ago

Mustang Bio files to sell common stock and warrants, no amount given

Jan 15, 2025, 7:00 AM EST - 1 year ago

Mustang Bio Registration statement: Registration Filing

2025-01-14T13:26:29.000Z - 1 year ago

Mustang Bio announces 1-for-50 reverse stock split

Jan 14, 2025, 8:00 AM EST - 1 year ago

Mustang Bio Announces Reverse Stock Split

Dec 6, 2024, 7:00 AM EST - 1 year ago

Mustang Bio Proxy statement: Proxy Filing

2024-11-22T21:55:07.000Z - 1 year ago

Mustang Bio files to sell 34.77M shares of common stock for holders

Nov 22, 2024, 7:00 AM EST - 1 year ago

Mustang Bio Registration statement: Registration Filing

2024-11-12T13:35:08.000Z - 1 year ago

Mustang Bio receives positive listing determination from Nasdaq

Nov 12, 2024, 8:30 AM EST - 1 year ago

Mustang Bio Receives Positive Listing Determination from Nasdaq

2024-11-07T13:45:08.000Z - 1 year ago

Mustang Bio granted Orphan Drug Designation by U.S. FDA for MB-108

Nov 7, 2024, 8:30 AM EST - 1 year ago

Mustang Bio Granted Orphan Drug Designation by U.S. FDA for MB-108 (HSV-1 oncolytic virus) to Treat Malignant Glioma

Oct 24, 2024, 2:10 PM EDT - 1 year ago

Mustang Bio Announces Exercise of Warrants for $4 Million Gross Proceeds

2024-10-22T20:21:36.000Z - 1 year ago

Mustang Bio treatment of malignant glioma granted FDA orphan status

2024-09-17T10:10:25.000Z - 2 years ago

Mustang Bio rating placed under review at H.C. Wainwright

Aug 13, 2024, 7:00 AM EDT - 2 years ago

Mustang Bio Quarterly report: Q2 2024

2024-07-19T21:28:27.000Z - 2 years ago

Mustang Bio files to sell 6.5M shares of common stock for holders

Jul 19, 2024, 8:00 AM EDT - 2 years ago

Mustang Bio Registration statement: Registration Filing

Jun 28, 2024, 8:00 AM EDT - 2 years ago

Diamond Equity Research Releases Update Note on Enveric Biosciences Inc. (NASDAQ: ENVB)

ENVB

Jun 21, 2024, 4:01 PM EDT - 2 years ago

Mustang Bio Announces Closing of $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

2024-06-20T15:17:16.000Z - 2 years ago

Biotech Alert: Searches spiking for these stocks today

AVTE BNTX CARA GOSS ITCI MIRM OVID

Jun 20, 2024, 8:00 AM EDT - 2 years ago

Mustang Bio Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jun 18, 2024, 2:52 AM EDT - 2 years ago

Why are Mustang Bio shares (MBIO) up almost 500%?

Jun 17, 2024, 8:30 AM EDT - 2 years ago

Mustang Bio Announces Favorable Efficacy and Safety Data from Complete Waldenstrom Macroglobulinemia Cohort of Phase 1/2 Clinical Trial of MB-106, CD20-Targeted Autologous CAR-T Therapy

May 31, 2024, 8:00 AM EDT - 2 years ago

Mustang Bio Registration statement: Registration Filing

May 15, 2024, 7:00 AM EDT - 2 years ago

Mustang Bio Quarterly report: Q1 2024

May 2, 2024, 4:01 PM EDT - 2 years ago

Mustang Bio Announces Closing of $4 Million Public Offering

Apr 29, 2024, 8:00 PM EDT - 2 years ago

Mustang Bio Announces Pricing of $4 Million Public Offering

Apr 29, 2024, 8:00 AM EDT - 2 years ago

Mustang Bio Registration statement: Registration Filing

Apr 29, 2024, 8:00 AM EDT - 2 years ago

Mustang Bio Registration statement: Registration Filing

Apr 29, 2024, 8:00 AM EDT - 2 years ago

Mustang Bio Registration statement: Registration Filing

Apr 2, 2024, 8:00 AM EDT - 2 years ago

Mustang Bio Registration statement: Registration Filing

Mar 28, 2024, 9:00 AM EDT - 2 years ago

Mustang Bio Announces Vision for CAR T-Cell Therapy Platform Expansion into Autoimmune Diseases

Mar 15, 2024, 8:00 AM EDT - 2 years ago

Mustang Bio Registration statement: Registration Filing

Mar 11, 2024, 4:05 PM EDT - 2 years ago

Mustang Bio Reports Full-Year 2023 Financial Results and Recent Corporate Highlights

Mar 11, 2024, 8:00 AM EDT - 2 years ago

Mustang Bio Annual report: Q4 2023

Mar 11, 2024, 8:00 AM EDT - 2 years ago

Mustang Bio Earnings release: Q4 2023

Mar 7, 2024, 7:30 AM EST - 2 years ago

Mustang Bio Announces Publication in Nature Medicine of Data from Phase 1 Trial Evaluating MB-101 IL13Rα2-targeted CAR T-Cells in High-Grade Glioma

Jan 11, 2024, 8:30 AM EST - 2 years ago

Mustang Bio to Participate in the B. Riley Securities 4th Annual Oncology Conference

Dec 12, 2023, 7:00 AM EST - 2 years ago

Mustang Bio Registration statement: Registration Filing

Dec 11, 2023, 8:30 AM EST - 2 years ago

Mustang Bio Presents Updated Phase 1/2 Multicenter Clinical Data for MB-106 at the 2023 American Society of Hematology (ASH) Annual Meeting

Nov 14, 2023, 4:05 PM EST - 3 years ago

Mustang Bio Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights

Nov 14, 2023, 7:00 AM EST - 3 years ago

Mustang Bio Quarterly report: Q3 2023

Nov 14, 2023, 7:00 AM EST - 3 years ago

Mustang Bio Earnings release: Q3 2023

Nov 2, 2023, 9:28 AM EDT - 3 years ago

Mustang Bio Announces MB-106 CD20-Targeted CAR-T Data Selected for Presentation at 65th American Society of Hematology (ASH) Annual Meeting

Oct 30, 2023, 2:15 PM EDT - 3 years ago

Mustang Bio Announces Closing of $4.4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Oct 26, 2023, 12:30 PM EDT - 3 years ago

Mustang Bio Announces $4.4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Oct 26, 2023, 9:00 AM EDT - 3 years ago

Mustang Bio Announces FDA Acceptance of IND Application for MB-109, a Novel Combination of MB-101 (IL13Rα2‐targeted CAR-T cell therapy) and MB-108 (HSV-1 oncolytic virus), for the Treatment of Recurrent Glioblastoma and High-Grade Astrocytoma

Sep 7, 2023, 8:15 AM EDT - 3 years ago

Mustang Bio to Participate in Upcoming September 2023 Investor Conferences

Aug 16, 2023, 8:00 AM EDT - 3 years ago

Mustang Bio Announces First Data from Ongoing Multicenter Phase 1/2 Clinical Trial Evaluating MB-106 CAR-T Cell Therapy

Aug 14, 2023, 4:05 PM EDT - 3 years ago

Mustang Bio Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights

Aug 14, 2023, 7:00 AM EDT - 3 years ago

Mustang Bio Quarterly report: Q2 2023

Aug 14, 2023, 7:00 AM EDT - 3 years ago

Mustang Bio Earnings release: Q2 2023

Aug 3, 2023, 8:00 AM EDT - 3 years ago

Mustang Bio to Participate in Two August 2023 Investor Conferences

Jul 31, 2023, 8:30 AM EDT - 3 years ago

Mustang Bio Announces Amendment and Closing of Strategic Manufacturing Partnership Transaction with uBriGene (Boston) Biosciences

Jul 6, 2023, 8:00 AM EDT - 3 years ago

Mustang Bio Announces Participation in Upcoming Scientific Meetings

Jun 15, 2023, 4:01 PM EDT - 3 years ago

Mustang Bio Announces Final Results from Follicular Lymphoma Cohort of Single-Institution Phase 1/2 Clinical Trial of MB-106, CD20-Targeted Autologous CAR T Therapy

Jun 12, 2023, 8:00 AM EDT - 3 years ago

Mustang Bio Announces Updated Results from Waldenstrom Macroglobulinemia Cohort of Ongoing Phase 1/2 Clinical Trial of MB-106, CD20-Targeted Autologous CAR T Therapy

May 18, 2023, 8:03 AM EDT - 3 years ago

Mustang Bio Announces Strategic Manufacturing Partnership and Portfolio Updates

May 12, 2023, 4:05 PM EDT - 3 years ago

Mustang Bio Reports First Quarter 2023 Financial Results and Recent Corporate Highlights

May 12, 2023, 7:00 AM EDT - 3 years ago

Mustang Bio Quarterly report: Q1 2023

May 12, 2023, 7:00 AM EDT - 3 years ago

Mustang Bio Earnings release: Q1 2023

May 11, 2023, 4:03 PM EDT - 3 years ago

Mustang Bio Announces Upcoming Presentations of Clinical Data from Phase 1/2 Trial of MB-106, a CD20-Targeted Autologous CAR T Cell Therapy

Apr 28, 2023, 8:00 AM EDT - 3 years ago

Mustang Bio Proxy statement: Proxy Filing

Apr 28, 2023, 8:00 AM EDT - 3 years ago

Mustang Bio Proxy statement: Proxy Filing

Mar 29, 2023, 4:15 PM EDT - 3 years ago

Mustang Bio Reports Full-Year 2022 Financial Results and Recent Corporate Highlights

Mar 29, 2023, 7:00 AM EDT - 3 years ago

Mustang Bio Annual report: Q4 2022

Mar 29, 2023, 7:00 AM EDT - 3 years ago

Mustang Bio Earnings release: Q4 2022

Mar 28, 2023, 8:30 AM EDT - 3 years ago

Mustang Bio to Participate in Cantor's The Future of Oncology Virtual Symposium

Jan 17, 2023, 8:15 AM EST - 3 years ago

Mustang Bio to Participate in the B. Riley Securities' 3rd Annual Oncology Conference

Dec 19, 2022, 8:30 AM EST - 3 years ago

Mustang Bio Provides CAR T Cell Therapy Portfolio Updates and 2023 Anticipated Milestones

Nov 14, 2022, 4:05 PM EST - 4 years ago

Mustang Bio Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights

Nov 14, 2022, 7:00 AM EST - 4 years ago

Mustang Bio Quarterly report: Q3 2022

Nov 14, 2022, 7:00 AM EST - 4 years ago

Mustang Bio Earnings release: Q3 2022

Oct 27, 2022, 8:00 AM EDT - 4 years ago

Mustang Bio Announces Phase 1/2 Clinical Trial Data of MB-106, a First-in-Class CD20-targeted, Autologous CAR T Cell Therapy, to be Presented at 11th International Workshop for Waldenstrom's Macroglobulinemia

Oct 6, 2022, 8:30 AM EDT - 4 years ago

Mustang Bio Announces First Patient Treated in Its Multicenter Phase 1/2 Clinical Trial of MB-106, a First-in-Class CD20-targeted, Autologous CAR T Cell Therapy to Treat B-cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia

Sep 8, 2022, 8:00 AM EDT - 4 years ago

Mustang Bio to Participate in Upcoming September 2022 Investor Conferences